The role of ErbB inhibitors in trastuzumab resistance

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The ErbB family of receptors and ligands is a complex, delicately balanced system involved in the growth and differentiation of normal human cells as well as neoplasms. Targeting this system with therapies that inhibit ErbB receptor activity in cancer patients has been somewhat successful, but resistance to ErbB inhibitor monotherapy is substantial. An understanding of the biology of ErbB receptor inhibitors is necessary to determine how best to utilize them in treatment regimens. Experimental evidence has provided valuable insights regarding mechanisms involved in resistance, and indicates that resistance can be reversed in some models. Ongoing studies in patients are evaluating whether agents that target both the epidermal growth factor (EGFR, ErbB-1) and ErbB-2 (HER-2) receptors can prevent or delay resistance in patients with metastatic breast cancer that overexpresses HER-2. With a better understanding of the biology of breast cancer, and with several novel ErbB receptor inhibitors in development, continued progress for improved patient outcomes is expected.

Original languageEnglish
Pages (from-to)16-19
Number of pages4
JournalOncologist
Volume9
Issue numberSUPPL. 3
StatePublished - 2004

Fingerprint

Breast Neoplasms
Epidermal Growth Factor
Neoplasms
Ligands
Trastuzumab
ErbB Receptors
Therapeutics
Growth

Keywords

  • Breast cancer
  • Resistance
  • Trastuzumab
  • Tyrosine kinase receptor

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

The role of ErbB inhibitors in trastuzumab resistance. / Miller, Kathy.

In: Oncologist, Vol. 9, No. SUPPL. 3, 2004, p. 16-19.

Research output: Contribution to journalArticle

Miller, Kathy. / The role of ErbB inhibitors in trastuzumab resistance. In: Oncologist. 2004 ; Vol. 9, No. SUPPL. 3. pp. 16-19.
@article{e524aa8c6be4433586d6dc3cc1796af5,
title = "The role of ErbB inhibitors in trastuzumab resistance",
abstract = "The ErbB family of receptors and ligands is a complex, delicately balanced system involved in the growth and differentiation of normal human cells as well as neoplasms. Targeting this system with therapies that inhibit ErbB receptor activity in cancer patients has been somewhat successful, but resistance to ErbB inhibitor monotherapy is substantial. An understanding of the biology of ErbB receptor inhibitors is necessary to determine how best to utilize them in treatment regimens. Experimental evidence has provided valuable insights regarding mechanisms involved in resistance, and indicates that resistance can be reversed in some models. Ongoing studies in patients are evaluating whether agents that target both the epidermal growth factor (EGFR, ErbB-1) and ErbB-2 (HER-2) receptors can prevent or delay resistance in patients with metastatic breast cancer that overexpresses HER-2. With a better understanding of the biology of breast cancer, and with several novel ErbB receptor inhibitors in development, continued progress for improved patient outcomes is expected.",
keywords = "Breast cancer, Resistance, Trastuzumab, Tyrosine kinase receptor",
author = "Kathy Miller",
year = "2004",
language = "English",
volume = "9",
pages = "16--19",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "SUPPL. 3",

}

TY - JOUR

T1 - The role of ErbB inhibitors in trastuzumab resistance

AU - Miller, Kathy

PY - 2004

Y1 - 2004

N2 - The ErbB family of receptors and ligands is a complex, delicately balanced system involved in the growth and differentiation of normal human cells as well as neoplasms. Targeting this system with therapies that inhibit ErbB receptor activity in cancer patients has been somewhat successful, but resistance to ErbB inhibitor monotherapy is substantial. An understanding of the biology of ErbB receptor inhibitors is necessary to determine how best to utilize them in treatment regimens. Experimental evidence has provided valuable insights regarding mechanisms involved in resistance, and indicates that resistance can be reversed in some models. Ongoing studies in patients are evaluating whether agents that target both the epidermal growth factor (EGFR, ErbB-1) and ErbB-2 (HER-2) receptors can prevent or delay resistance in patients with metastatic breast cancer that overexpresses HER-2. With a better understanding of the biology of breast cancer, and with several novel ErbB receptor inhibitors in development, continued progress for improved patient outcomes is expected.

AB - The ErbB family of receptors and ligands is a complex, delicately balanced system involved in the growth and differentiation of normal human cells as well as neoplasms. Targeting this system with therapies that inhibit ErbB receptor activity in cancer patients has been somewhat successful, but resistance to ErbB inhibitor monotherapy is substantial. An understanding of the biology of ErbB receptor inhibitors is necessary to determine how best to utilize them in treatment regimens. Experimental evidence has provided valuable insights regarding mechanisms involved in resistance, and indicates that resistance can be reversed in some models. Ongoing studies in patients are evaluating whether agents that target both the epidermal growth factor (EGFR, ErbB-1) and ErbB-2 (HER-2) receptors can prevent or delay resistance in patients with metastatic breast cancer that overexpresses HER-2. With a better understanding of the biology of breast cancer, and with several novel ErbB receptor inhibitors in development, continued progress for improved patient outcomes is expected.

KW - Breast cancer

KW - Resistance

KW - Trastuzumab

KW - Tyrosine kinase receptor

UR - http://www.scopus.com/inward/record.url?scp=2942616454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942616454&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 16

EP - 19

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - SUPPL. 3

ER -